# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Dermatomyositis
- **MONDO ID:**  (if available)
- **Category:** Autoimmune

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Dermatomyositis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2025-12-18T09:54:39.205453

1. musai2024recentupdateson pages 1-2
2. honda2024contributionofcomplement pages 1-3
3. cristofori2025dermatomyositisanarrative pages 2-3
4. paik2025brepocitinibapotent pages 1-2
5. harada2024baricitinibforantimelanoma pages 7-8
6. cristofori2025dermatomyositisanarrative pages 3-4
7. rocca2023targetingintracellularpathways pages 3-4
8. ma2024therapeuticefficacyand pages 1-2
9. honda2024contributionofcomplement pages 8-10
10. wallwork2024currentevidencefor pages 1-3
11. kobayashi2024advancesinjuvenile pages 13-14
12. ali2025dermatomyositisfocuson pages 1-2
13. kim2024updatesonefficacy pages 3-4
14. kim2024updatesonefficacy pages 13-14
15. kim2025juveniledermatomyositisupdates pages 1-2
16. https://doi.org/10.3233/jnd-230168;
17. https://doi.org/10.1007/s11926-024-01164-7;
18. https://doi.org/10.3390/children11091046
19. https://doi.org/10.7759/cureus.88601;
20. https://doi.org/10.1007/s00281-025-01054-9
21. https://doi.org/10.3389/fimmu.2024.1382728;
22. https://doi.org/10.1007/s00296-024-05551-2;
23. https://doi.org/10.1080/14656566.2024.2392021;
24. https://doi.org/10.55563/clinexprheumatol/eeglsa
25. https://doi.org/10.3233/jnd-230168
26. https://doi.org/10.3389/fimmu.2023.1151695
27. https://doi.org/10.3389/fimmu.2024.1382728
28. https://doi.org/10.1007/s00296-024-05551-2
29. https://doi.org/10.1080/1744666x.2024.2312819
30. https://doi.org/10.1080/14656566.2024.2392021
31. https://doi.org/10.1007/s11926-024-01164-7
32. https://doi.org/10.7759/cureus.88601
33. https://doi.org/10.3233/jnd-230168,
34. https://doi.org/10.7759/cureus.88601,
35. https://doi.org/10.1007/s11926-024-01164-7,
36. https://doi.org/10.3390/children11091046,
37. https://doi.org/10.1007/s00281-025-01054-9,
38. https://doi.org/10.3389/fimmu.2024.1382728,
39. https://doi.org/10.1007/s00296-024-05551-2,
40. https://doi.org/10.1080/14656566.2024.2392021,
41. https://doi.org/10.55563/clinexprheumatol/eeglsa,
42. https://doi.org/10.3389/fmed.2023.1158768,
43. https://doi.org/10.1080/1744666x.2024.2312819,
44. https://doi.org/10.1007/s40272-024-00658-2,